
Affair, dowry case threat: Police uncovers mystery behind Madhya Pradesh's family suicide
Manohar Lodhi (45), his 70-year-old mother, and his two teenage children died after consuming Sulphas tablets on the night of July 25–26. The investigation into the case has revealed that the mass suicides might have been triggered by Manohar's wife's alleged affair.
According to NDTV, Manohar Lodhi's wife, Draupadi, was having an affair with his childhood friend, Surendra. The family was aware of the illicit relationship and had asked them to break it off. However, both allegedly refused, stating they could not live without each other.
The incident occurred in Tehar village, about 12 km away from the Sagar district headquarters.
The situation escalated when Draupadi reportedly threatened to file false dowry harassment cases against the family if they continued to oppose the relationship. Her daughter had also witnessed her mother and Surendra in intimate situations, police said.
Tired of the mental and societal pressure, Draupadi's husband, his mother, and two children consumed Sulphas tablets.
While Manohar's mother, Phulrani, and son, Ankit, died on the spot, their daughter, Shivani, breathed her last during treatment at a hospital. Manohar Lodhi was referred to the Sagar district hospital but died en route, the police officer said.
On the day of the incident, Nandram Singh Lodhi said he heard his brother, Manohar, vomiting downstairs in July.
After Nandram alerted his neighbour, he summoned an ambulance. However, by the time the ambulance arrived, Nandram's mother and nephew had died.
On duty doctor at Khurai civil hospital, Varsha Kesharwani, stated that four individuals had consumed Sulphas tablets. They were brought to the hospital in the wee hours.
Note: Discussing suicides can be triggering for some. However, suicides are preventable. A few major suicide prevention helpline numbers in India are 011-23389090 from Sumaitri (Delhi-based) and 044-24640050 from Sneha Foundation (Chennai-based).

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
2 hours ago
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
&w=3840&q=100)

Business Standard
3 hours ago
- Business Standard
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.


News18
4 hours ago
- News18
Nadda urged to give permission for MBBS admission in two Odisha medical colleges
Agency: PTI Bhubaneswar, Aug 5 (PTI) The Odisha government on Tuesday urged Union Health Minister Jagat Prakash Nadda to grant permission for admission in 100 MBBS seats in two new government-run medical colleges of the state for the academic session 2025-26. Odisha Health & Family Welfare Minister Mukesh Mahaling, along with Union Education Minister Dharmendra Pradhan who hailed from the state, and others, met Nadda in New Delhi and raised this demand. Mahaling requested Nadda to issue for Letter of Permission (LoP) for admission of 100 MBBS seats in the 2025-26 session in each of Pavitra Mohan Pradhan Medical College (PMPMC), Talcher and Government Medical College (GMC), Phulbani, a statement issued by the Odisha health department said here. Both institutions have recently been established to cater to the growing demand in the medical education sector of Odisha. The respective deans and principals of these two institutions had already submitted their applications for LoP on January 18, 2025, through the National Medical Commission (NMC) portal, the statement said. The NMC teams had also conducted physical inspections of the Pavitra Mohan Pradhan Medical College in June 2025 and Government Medical College, Phulbani in May last. The state government has provided the budgetary grants to enhance facilities and ensure quality medical education at both institutions, it said. When the LoP is granted, two more government medical colleges will be added to the state's healthcare infrastructure, increasing the total number from 14 to 16 government medical colleges. Consequently, the total number of MBBS seats in government institutions will increase to 1800. PTI BBM NN (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.